Clinical Research Directory

Inclusion Criteria: * Borderline or locally advanced pancreatic adenocarcinoma at diagnosis according to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines, version 1.2022 * Histo- or cytologically confirmed adenocarcinoma (preferably EUS-guided) * T1-4, Nx, M0 according to AJCC 8th edition * ECOG 0-1 and considered fit for the planned chemotherapy at the local hospital and surgery at the two national centers for BR/LAPC * Written informed patient consent Exclusion Criteria: * Co-morbidity precluding pancreatic surgery or chemotherapy * Contraindications to any of the drugs in the proposed treatment regimens * ECOG ≥2 * Neuropathy ≥ grade 2 according to Common Terminology Criteria for Adverse Events (CTCAE), version 6 * Granulocyte count \< 1500 per cubic millimetre (\< 1,5 x 109/L) * Platelet count \< 100 000 per cubic millimetre (\< 100 x 109/L) * Serum creatinine \> 1.5 UNL (upper limit normal range) * Albumin \<2,5 g/dl (\<25 g/L) * Total bilirubin \>3 x ULN * ASAT (SGOT) and ALAT (SGPT) \>2.5 x institutional ULN * female patients in child-bearing age not using adequate contraception, pregnant or lactating women * mental or somatic disorders which could possibly interfere with informed consent, compliance or the planned treatments * previous oncologic treatment for PC within the past 5 years * participation in other clinical trial with an investigational product during the past 30 days * Any reason according to the investigator why the patient cannot comply with the protocol or is not suitable to participate